Evidence-Based Medicine
Copyright ©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Jun 14, 2014; 20(22): 6912-6917
Published online Jun 14, 2014. doi: 10.3748/wjg.v20.i22.6912
Table 2 Serum adipokine concentrations
Adiponectin, μg/mLLeptin, ng/mLTGF-β1, pg/mLChemerin, ng/mLResistin, ng/mLVisfatin, ng/mL
Crohn’s disease
Before treatment (n = 24)14.7 ± 19.48.0 ± 9.1a3152 ± 1137418 ± 19319.3 ± 12.5a23.2 ± 3.2a
Upon treatment (n = 24)11.7 ± 6.714.9 ± 15.1c3261 ± 1327344 ± 12717.9 ± 13.2a20.4 ± 4.8ac
Ulcerative colitis
Before treatment (n = 16)9.8 ± 4.18.6 ± 6.3a4378 ± 361421 ± 21423.2 ± 11.0a18.8 ± 5.3a
Upon treatment (n = 16)13.7 ± 5.39.2 ± 7.32877 ± 1761379 ± 20814.5 ± 4.0c21.0 ± 3.5a
Control group
Healthy subjects (n = 16)9.3 ± 3.016.5 ± 10.13027 ± 809355 ± 6910.7 ± 1.114.1 ± 5.4